Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant and

cancer
serum calcium
endocrine therapy
cancer treatment
estrogen
  • 161 views
  • 22 Jan, 2021
  • 14 locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or

  • 50 views
  • 01 Mar, 2021
  • 212 locations
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence of an aromatase inhibitor in first line followed by fulvestrant plus CDK4/6 in second line.

gilbert's syndrome
aromatase inhibitor
cancer
adenocarcinoma
metastasis
  • 71 views
  • 23 Jan, 2021
  • 72 locations
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

The goal of this clinical research study is to learn if fulvestrant and abemaciclib can help to control low-grade serous ovarian cancer. The safety of this drug combination will also be studied

  • 0 views
  • 23 Jan, 2021
  • 1 location
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or

  • 38 views
  • 27 Jan, 2021
  • 52 locations
A Study Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)

In post-menopausal metastatic hormone-responsive breast cancer women. This study is a two arm randomized trial to evaluate the effectiveness of dose-titration regimen of fulvestrant

carcinoma in situ
advanced breast cancer
immunostimulant
metastasis
carcinoma
  • 0 views
  • 07 Nov, 2020
  • 1 location
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

This is a phase IB/II clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole or Fulvestrant. Patients who have HR positive and HER2 negative

aromatase inhibitor
metastasis
endocrine therapy
HER2
fulvestrant
  • 34 views
  • 23 Jan, 2021
  • 4 locations
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2

her2-negative breast cancer
aromatase inhibitor
cish
HER2
human epidermal growth factor
  • 0 views
  • 03 Mar, 2021
  • 7 locations
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive

  • 15 views
  • 28 Jan, 2021
  • 42 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

aromatase inhibitor
metastasis
HER2
estrogen
measurable disease
  • 0 views
  • 27 Jan, 2021
  • 49 locations